Clinical Trial Update: Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) [Phase 1]

View source ↗

Summary

A Phase 1 study of Betalutin in relapsed or refractory diffuse large B-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Betalutin

Snippet

Sponsor: Nordic Nanovector | Conditions: Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2024-01-16